Xpovio (selinexor) vs Elrexfio (elranatamab-bcmm)
Xpovio (selinexor) vs Elrexfio (elranatamab-bcmm)
Xpovio (selinexor) is an oral selective inhibitor of nuclear export (SINE) compound that is approved for the treatment of multiple myeloma and certain types of diffuse large B-cell lymphoma, functioning by blocking the export of tumor suppressor proteins. Elrexfio (elranatamab-bcmm), on the other hand, is a bispecific antibody designed to target BCMA (B-cell maturation antigen) on myeloma cells and CD3 on T-cells, thereby facilitating the immune system's ability to recognize and destroy myeloma cells. When deciding between Xpovio and Elrexfio, it is crucial to consider the specific diagnosis, treatment history, potential side effects, and the mechanism of action of each medication, in consultation with a healthcare professional.
Difference between Xpovio and Elrexfio
Metric | Xpovio (selinexor) | Elrexfio (elranatamab-bcmm) |
---|---|---|
Generic name | Selinexor | Elranatamab-bcmm |
Indications | Multiple myeloma, diffuse large B-cell lymphoma | Under investigation for multiple myeloma |
Mechanism of action | Selective inhibitor of nuclear export | Bispecific antibody targeting BCMA and CD3 |
Brand names | Xpovio | Elrexfio |
Administrative route | Oral | Intravenous |
Side effects | Nausea, vomiting, fatigue, anorexia, weight loss | Currently under investigation |
Contraindications | Thrombocytopenia, neutropenia, sepsis | Currently under investigation |
Drug class | Antineoplastic agent | Monoclonal antibody |
Manufacturer | Karyopharm Therapeutics | Pfizer |
Efficacy
Xpovio (Selinexor) Efficacy in Multiple Myeloma
Xpovio (selinexor) is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound that has shown efficacy in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. The U.S. Food and Drug Administration (FDA) approved Xpovio in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Clinical trials have demonstrated that Xpovio, in combination with dexamethasone, can lead to a significant reduction in tumor burden in a subset of these heavily pretreated patients.
The approval of Xpovio for this indication was based on the results of the STORM study, a Phase 2b clinical trial that evaluated the drug's efficacy in patients with RRMM. In this study, Xpovio demonstrated a meaningful overall response rate (ORR), which is the proportion of patients with a partial or complete response to the therapy. The ORR observed in the trial provided evidence that Xpovio could offer a therapeutic benefit to patients who have limited treatment options due to the advanced nature of their disease.
Elrexfio (Elranatamab-bcmm) Efficacy in Multiple Myeloma
Elrexfio (elranatamab-bcmm), previously known as PF-06863135, is an investigational bispecific antibody that targets BCMA (B-cell maturation antigen) and CD3 on T cells. BCMA is commonly expressed on the surface of multiple myeloma cells. Elrexfio is designed to redirect T cells to engage and eliminate BCMA-expressing myeloma cells. While Elrexfio is not yet approved for use, it has shown promise in early clinical trials for the treatment of multiple myeloma.
In the ongoing clinical trials, Elrexfio has demonstrated an ability to induce responses in patients with relapsed or refractory multiple myeloma. The data from these trials suggest that Elrexfio can produce deep and durable responses, with a number of patients achieving a very good partial response (VGPR) or better. The efficacy of Elrexfio as a monotherapy is being further investigated in larger, more advanced clinical trials to confirm its potential benefits and to support its application for regulatory approval.
Regulatory Agency Approvals
Xpovio
Elrexfio
Access Xpovio or Elrexfio today
If Xpovio or Elrexfio are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us